Patents by Inventor Lucian V. DiPietro

Lucian V. DiPietro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230353959
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3K-? enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with PI3K-? signaling with the compounds and compositions of the disclosure.
    Type: Application
    Filed: June 9, 2023
    Publication date: November 2, 2023
    Inventors: Lucian V. DIPIETRO, Kelley C. SHORTSLEEVES, Thomas H. MCLEAN, Alexandre LARIVEE, Fabrizio GIORDANETTO
  • SHP2 phosphatase inhibitors and methods of use thereof
    Patent number: 11629145
    Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds ad compositions of the invention.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: April 18, 2023
    Assignees: D. E. Shaw Research, LLC, Relay Therapeutics, Inc.
    Inventors: Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Alexander M. Taylor, Lucian V. Dipietro, Elizabeth H. Kelley, André Lescarbeau, Mark Andrew Murcko, Levi Charles Thomas Pierce, Kelley C. Shortsleeves, W. Patrick Walters, Sathesh Bhat, Eric Therrien, Markus Kristofer Dahlgren
  • Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
    Patent number: 11591336
    Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions thereof and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: February 28, 2023
    Assignees: D. E. Shaw Research, LLC, Relay Therapeutics, Inc.
    Inventors: Alexander M. Taylor, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, Lucian V. DiPietro, W. Patrick Walters, Mark Andrew Murcko, Levi Charles Thomas Pierce, Yong Tang, Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Sathesh Bhat, Markus Kristofer Dahlgren, Eric Therrien
  • INHIBITORS OF RET
    Publication number: 20220315560
    Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Application
    Filed: February 11, 2022
    Publication date: October 6, 2022
    Inventors: Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro
  • Inhibitors of RET
    Patent number: 11279688
    Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: March 22, 2022
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro
  • INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR
    Publication number: 20210347756
    Abstract: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Application
    Filed: November 24, 2020
    Publication date: November 11, 2021
    Inventors: Neil Bifulco, JR., Lucian V. DiPietro, Brian L. Hodous, Chandrasekhar V. Miduturu
  • INHIBITORS OF RET
    Publication number: 20200407341
    Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Application
    Filed: January 29, 2020
    Publication date: December 31, 2020
    Inventors: Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro
  • Inhibitors of the fibroblast growth factor receptor
    Patent number: 10875837
    Abstract: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: December 29, 2020
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Neil Bifulco, Jr., Lucian V. DiPietro, Brian L. Hodous, Chandrasekhar V. Miduturu
  • 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
    Patent number: 10774070
    Abstract: Described herein are compounds, such as compounds of Formula (I) and pharmaceutically acceptable salts thereof, that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions, e.g.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: September 15, 2020
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Natasja Brooijmans, Lucian V. DiPietro, Paul E. Fleming, Joseph L. Kim, Steven Mark Wenglowsky, Yulian Zhang
  • PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS
    Publication number: 20200172546
    Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure.
    Type: Application
    Filed: May 25, 2018
    Publication date: June 4, 2020
    Inventors: Alexander M. Taylor, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, Lucian V. DiPietro, W. Patrick Walters, Mark Andrew Murcko, Levi Charles Thomas Pierce, Yong Tang, Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Sathesh Bhat, Markus Kristofer Dahlgren, Eric Therrien
  • INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR
    Publication number: 20200109127
    Abstract: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Application
    Filed: February 19, 2019
    Publication date: April 9, 2020
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Neil Bifulco, JR., Lucian V. DiPietro, Brian L. Hodous, Chandrasekhar V. Miduturu
  • Inhibitors of RET
    Patent number: 10584114
    Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: March 10, 2020
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro
  • SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20200062760
    Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds ad compositions of the invention.
    Type: Application
    Filed: October 24, 2017
    Publication date: February 27, 2020
    Inventors: Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Alexander M. Taylor, Lucian V. Dipietro, Elizabeth H. Kelley, André Lescarbeau, Mark Andrew Murcko, Levi Charles Thomas Pierce, Kelley C. Shortsleeves, W. Patrick Walters, Sathesh Bhat, Eric Therrien, Markus Kristofer Dahlgren
  • 2-(PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES AS RET INHIBITORS
    Publication number: 20190359591
    Abstract: Described herein are compounds, such as compounds of Formula (I) and pharmaceutically acceptable salts thereof, that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions, e.g.
    Type: Application
    Filed: December 20, 2018
    Publication date: November 28, 2019
    Applicant: BLUEPRINT MEDICINES CORPORATION
    Inventors: Natasja BROOIJMANS, Lucian V. DIPIETRO, Paul E. FLEMING, Joseph L. KIM, Steven Mark WENGLOWSKY, Yulian ZHANG
  • INHIBITORS OF RET
    Publication number: 20190185454
    Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Application
    Filed: July 20, 2018
    Publication date: June 20, 2019
    Inventors: Jason D. BRUBAKER, Joseph L. KIM, Kevin J. WILSON, Douglas WILSON, Lucian V. DIPIETRO
  • Compounds useful for treating disorders related to RET
    Patent number: 10227329
    Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: March 12, 2019
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Jason D. Brubaker, Timothy Guzi, Kevin J. Wilson, Lucian V. Dipietro, Yulian Zhang, Douglas Wilson, Paul E. Fleming
  • Inhibitors of the fibroblast growth factor receptor
    Patent number: 10221154
    Abstract: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: March 5, 2019
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Neil Bifulco, Jr., Lucian V. DiPietro, Brian L. Hodous, Chandrasekhar V. Miduturu
  • 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
    Patent number: 10202365
    Abstract: Described herein are compounds, such as compounds of Formula (I) and pharmaceutically acceptable salts thereof, that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions, e.g.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: February 12, 2019
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Natasja Brooijmans, Lucian V. DiPietro, Paul E. Fleming, Joseph L. Kim, Steven Mark Wenglowsky, Yulian Zhang
  • Compounds useful for treating disorders related to RET
    Patent number: 10035789
    Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: July 31, 2018
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Jason D. Brubaker, Lucian V. Dipietro
  • Inhibitors of RET
    Patent number: 10030005
    Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: July 24, 2018
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro